Experience

Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering…

Davis Polk advised Oryzon Genomics, S.A. on its private placement of approximately 7,273,000 of its ordinary shares pursuant to a capital increase. The offering consisted of two tranches: a…

Davis Polk advised the representatives of the several underwriters in connection with the $296 million SEC-registered offering of 9,545,000 shares of common stock of 1Life Healthcare,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…